- Legal Challenges: PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is embroiled in a securities fraud class action lawsuit alleging artificial boosting of financial results.
- Upcoming Earnings: The medical device company is set to release its earnings report on August 4, 2026, with an expected EPS of -$0.46 and revenue of $92.77 million.
- Mixed Financials: Despite a negative P/E ratio of -10.10, PROCEPT BioRobotics maintains a strong balance sheet with a low Debt-to-Equity ratio of 0.15 and a high Current Ratio of 6.73.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a medical device company that develops surgical robotics. Its main product is the AquaBeam Robotic System, which uses its proprietary Aquablation therapy to treat patients with enlarged prostates. The company is currently facing significant legal challenges from investors.
On August 4, 2026, PROCEPT BioRobotics is scheduled to release its earnings report after the market closes. The market expects an earnings per share of -$0.46 on revenue of about $92.77 million. This upcoming report follows a period of major disruption for the company and its shareholders.
The company's stock recently fell 18% after a securities fraud class action lawsuit was announced. The lawsuit claims PROCEPT BioRobotics artificially boosted its financial results. It alleges the company used a large discount program to push customers into placing bulk orders, which may violate federal securities laws.
As highlighted by GlobeNewsWire, the legal action focuses on claims that PROCEPT BioRobotics pulled sales in from future quarters. This was allegedly done to create the appearance that the company was meeting sales expectations for its single-use handpiece. This practice led to high customer inventory and unexpected underperformance.
This situation is reflected in some of the company's financial metrics. PROCEPT BioRobotics has a negative trailing twelve-month Price-to-Earnings (P/E) ratio of -10.10. A negative P/E ratio indicates that the company has had negative earnings, or a net loss, over the past year.
Despite these challenges, the company's balance sheet shows some stability. PROCEPT BioRobotics maintains a low Debt-to-Equity ratio of 0.15, suggesting it has little debt compared to its equity. It also has a strong current ratio of 6.73, which shows a solid ability to cover its short-term financial obligations.